Delayed
Bombay S.E.
09:59:41 02/05/2024 BST
|
5-day change
|
1st Jan Change
|
423.4
INR
|
+0.13%
|
|
+2.09%
|
+4.33%
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
29,060
|
36,510
|
75,120
|
75,964
|
70,374
|
102,486
|
-
|
-
|
Enterprise Value (EV)
1 |
37,495
|
36,510
|
82,206
|
82,880
|
78,577
|
110,612
|
110,807
|
110,512
|
P/E ratio
|
12.3
x
|
10.9
x
|
13.8
x
|
18.5
x
|
13.8
x
|
24.8
x
|
17.1
x
|
14.2
x
|
Yield
|
0.87%
|
0.7%
|
0.49%
|
0.49%
|
0.52%
|
0.33%
|
0.33%
|
0.33%
|
Capitalization / Revenue
|
1.28
x
|
1.4
x
|
2.32
x
|
2.02
x
|
1.56
x
|
2.25
x
|
1.95
x
|
1.72
x
|
EV / Revenue
|
1.65
x
|
1.4
x
|
2.54
x
|
2.2
x
|
1.74
x
|
2.42
x
|
2.11
x
|
1.86
x
|
EV / EBITDA
|
9.76
x
|
6.95
x
|
9.61
x
|
11.5
x
|
8.6
x
|
12.8
x
|
9.94
x
|
8.46
x
|
EV / FCF
|
-219
x
|
12.5
x
|
51
x
|
-126
x
|
24
x
|
113
x
|
102
x
|
18.8
x
|
FCF Yield
|
-0.46%
|
7.99%
|
1.96%
|
-0.79%
|
4.18%
|
0.89%
|
0.98%
|
5.33%
|
Price to Book
|
1.9
x
|
1.98
x
|
3.46
x
|
2.94
x
|
2.48
x
|
3.25
x
|
2.72
x
|
2.3
x
|
Nbr of stocks (in thousands)
|
254,248
|
254,248
|
247,675
|
248,006
|
242,043
|
242,369
|
-
|
-
|
Reference price
2 |
114.3
|
143.6
|
303.3
|
306.3
|
290.8
|
422.8
|
422.8
|
422.8
|
Announcement Date
|
09/05/19
|
02/06/20
|
11/05/21
|
18/05/22
|
16/05/23
|
-
|
-
|
-
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
22,792
|
25,986
|
32,375
|
37,649
|
45,119
|
45,623
|
52,564
|
59,493
|
EBITDA
1 |
3,840
|
5,253
|
8,552
|
7,222
|
9,138
|
8,665
|
11,151
|
13,068
|
EBIT
1 |
2,786
|
3,884
|
7,038
|
5,636
|
7,293
|
6,677
|
8,808
|
10,130
|
Operating Margin
|
12.22%
|
14.94%
|
21.74%
|
14.97%
|
16.16%
|
14.64%
|
16.76%
|
17.03%
|
Earnings before Tax (EBT)
1 |
2,768
|
4,256
|
7,044
|
5,580
|
6,872
|
5,602
|
7,977
|
9,582
|
Net income
1 |
2,364
|
3,354
|
5,495
|
4,128
|
5,166
|
4,184
|
6,040
|
7,327
|
Net margin
|
10.37%
|
12.91%
|
16.97%
|
10.96%
|
11.45%
|
9.17%
|
11.49%
|
12.32%
|
EPS
2 |
9.280
|
13.15
|
21.95
|
16.60
|
21.00
|
17.02
|
24.72
|
29.87
|
Free Cash Flow
1 |
-171.6
|
2,917
|
1,611
|
-656.5
|
3,281
|
979
|
1,088
|
5,885
|
FCF margin
|
-0.75%
|
11.23%
|
4.98%
|
-1.74%
|
7.27%
|
2.15%
|
2.07%
|
9.89%
|
FCF Conversion (EBITDA)
|
-
|
55.53%
|
18.84%
|
-
|
35.9%
|
11.3%
|
9.76%
|
45.03%
|
FCF Conversion (Net income)
|
-
|
86.97%
|
29.33%
|
-
|
63.51%
|
23.4%
|
18.01%
|
80.32%
|
Dividend per Share
2 |
1.000
|
1.000
|
1.500
|
1.500
|
1.500
|
1.375
|
1.375
|
1.375
|
Announcement Date
|
09/05/19
|
02/06/20
|
11/05/21
|
18/05/22
|
16/05/23
|
-
|
-
|
-
|
Fiscal Period: March |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
8,445
|
7,993
|
8,498
|
8,883
|
9,968
|
10,300
|
10,196
|
11,555
|
11,471
|
11,955
|
9,855
|
11,215
|
12,346
|
12,500
|
EBITDA
1 |
2,116
|
2,020
|
2,014
|
1,512
|
1,737
|
1,927
|
2,115
|
2,429
|
2,313
|
2,281
|
1,368
|
1,880
|
2,368
|
2,793
|
EBIT
|
1,747
|
1,575
|
1,620
|
1,113
|
1,345
|
1,525
|
-
|
1,988
|
1,829
|
1,794
|
-
|
1,354
|
1,869
|
2,068
|
Operating Margin
|
20.69%
|
19.71%
|
19.07%
|
12.53%
|
13.49%
|
14.81%
|
-
|
17.21%
|
15.95%
|
15.01%
|
-
|
12.07%
|
15.14%
|
16.54%
|
Earnings before Tax (EBT)
1 |
1,839
|
1,540
|
1,629
|
1,102
|
1,348
|
1,501
|
1,659
|
1,904
|
1,669
|
1,640
|
654.7
|
1,169
|
1,704
|
1,924
|
Net income
1 |
1,468
|
1,276
|
1,202
|
806.8
|
1,009
|
1,110
|
1,276
|
1,451
|
1,243
|
1,196
|
479
|
1,112
|
1,295
|
1,738
|
Net margin
|
17.38%
|
15.96%
|
14.14%
|
9.08%
|
10.12%
|
10.78%
|
12.51%
|
12.56%
|
10.84%
|
10%
|
4.86%
|
9.91%
|
10.49%
|
13.91%
|
EPS
2 |
-
|
-
|
-
|
-
|
-
|
4.460
|
5.130
|
5.820
|
5.100
|
4.930
|
1.980
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
28/01/21
|
11/05/21
|
27/07/21
|
12/11/21
|
08/02/22
|
18/05/22
|
09/08/22
|
20/10/22
|
24/01/23
|
16/05/23
|
09/08/23
|
-
|
-
|
-
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
8,434
|
-
|
7,086
|
6,916
|
8,203
|
8,126
|
8,321
|
8,026
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
2.196
x
|
-
|
0.8285
x
|
0.9576
x
|
0.8976
x
|
0.9378
x
|
0.7462
x
|
0.6142
x
|
Free Cash Flow
1 |
-172
|
2,917
|
1,611
|
-657
|
3,281
|
979
|
1,088
|
5,885
|
ROE (net income / shareholders' equity)
|
16.7%
|
19.9%
|
27.4%
|
17.3%
|
19.1%
|
13.5%
|
16.8%
|
17.6%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
60.20
|
72.50
|
87.70
|
104.0
|
117.0
|
130.0
|
155.0
|
184.0
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
2,794
|
1,845
|
2,713
|
3,977
|
4,107
|
6,023
|
5,734
|
5,165
|
Capex / Sales
|
12.26%
|
7.1%
|
8.38%
|
10.56%
|
9.1%
|
13.2%
|
10.91%
|
8.68%
|
Announcement Date
|
09/05/19
|
02/06/20
|
11/05/21
|
18/05/22
|
16/05/23
|
-
|
-
|
-
|
Last Close Price
422.8
INR Average target price
483.4
INR Spread / Average Target +14.33% Consensus |
1st Jan change
|
Capi.
|
---|
| +4.33% | 1.23B | | +33.25% | 699B | | +26.97% | 571B | | -3.55% | 364B | | +18.16% | 326B | | +4.36% | 286B | | +15.45% | 236B | | +5.18% | 198B | | -10.18% | 194B | | -3.69% | 149B |
Other Pharmaceuticals
|